Immune Modulators for Treating COVID-19

NCT04593940 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1971

Enrollment

OTHER

Sponsor class

Conditions

Covid19

Interventions

DRUG: Infliximab
DRUG: Abatacept
DRUG: Remdesivir
DRUG: cenicriviroc (closed to enrollment as of 3-Sep-2021)

Sponsor

Daniel Benjamin

Collaborators

[object Object]
[object Object]